explore -WSS

explore

author：Wikipedia 2025-09-30 00:35:28 - browse：48634

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Congress gives doctors Medicare pay bump

hotspot

WSS

House looks to weaken Medicare negotiation

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Pfizer highlights cancer drugs it thinks could reignite investor interest

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

A Q&A with Aletha Maybank, AMA’s chief health equity officer

hotspot

explore

knowledge

Jerome Adams on the need for new antivirals for Covid

Following judge's order, DOJ releases slightly less

How one medical school became remarkably diverse

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

BioMarin wins approval for gene therapy to treat hemophilia A

Israel withdraws forces after 2

Supreme Court strikes down use of affirmative action

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

Novavax promises a turnaround & Lilly roils the obesity market

A Q&A with Aletha Maybank, AMA’s chief health equity officer

hotspot

Princess Kate attends Wimbledon with Roger Federer: See the photos

A bus careens into a gulch in southern Mexico, leaving 27 people dead

Pfizer highlights cancer drugs it thinks could reignite investor interest

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Condition critical? Britain's beloved but battered National Health Service turns 75

EU moves toward latest gene techniques in food production to counter climate change, shortages

focus

knowledge

hotspot

focus